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Abstract
Background: Gastrointestinal Stromal Tumours (GISTs) are the most common mesenchymal tumours. Currently,
different pharmacological and surgical options are used to treat localised and metastatic GISTs, although this research
field is broad and the body of evidence is scattered and expanding. Our objectives are to identify, describe and
organise the current available evidence for GIST through an evidence mapping approach.
Methods: We followed the methodology of Global Evidence Mapping (GEM). We searched Pubmed, EMBASE, The
Cochrane Library and Epistemonikos in order to identify systematic reviews (SRs) with or without meta-analyses
published between 1990 and March 2016. Two authors assessed eligibility and extracted data. Methodological
quality of the included systematic reviews was assessed using AMSTAR. We organised the results according to
identified PICO questions and presented the evidence map in tables and a bubble plot.
Results: A total of 17 SRs met eligibility criteria. These reviews included 66 individual studies, of which three quarters
were either observational or uncontrolled clinical trials. Overall, the quality of the included SRs was moderate or high. In
total, we extracted 14 PICO questions from them and the corresponding results mostly favoured the intervention arm.
Conclusions: The most common type of study used to evaluate therapeutic interventions in GIST sarcomas has been
non-experimental studies. However, the majority of the interventions are reported as beneficial or probably beneficial
by the respective authors of SRs. The evidence mapping is a useful and reliable methodology to identify and present
the existing evidence about therapeutic interventions.
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Background
Sarcomas are rare malignant tumours of mesenchyme
origin that occur in connective tissue. They can be split
up into dozens of histological categories, which may
develop at any age including childhood, can affect any
anatomical localisation, and are of varying aggressive-
ness, even within the same histological subtype [1].
There are three main types of sarcoma corresponding to
different clinicopathological entities which require a
multidisciplinary approach: bone sarcomas, visceral
(GIST being the most typical) and soft tissue sarcoma
[2]. Gastrointestinal Stromal Tumours (GISTs) are the
most common mesenchymal tumours [3, 4]. They
constitute 1% to 3% of all malignant gastrointestinal
tumours [5].
Classically, systematic reviews (SRs) summarise the
results of available healthcare studies and provide a high
amount of evidence on the effectiveness of healthcare inter-
ventions [6]. However, SRs frequently address very specific
questions, preventing them from providing a comprehen-
sive overview of a given topic [7, 8]. To overcome this bar-
rier, new formats of review (e.g., scoping reviews, evidence
map, rapid review, etc.) have been developed [9–11], allow-
ing an understanding of the extent and distribution of
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evidence in a broad clinical area, highlighting both what is
known and any gaps in evidence. [10].
In 2007, the Global Mapping Initiative (GEM) was
established as a collaboration of clinical research and
policy stakeholders to provide an overview of existing
research about traumatic brain injury and spinal cord
injury [12]. Evidence mapping is an emerging tool to sys-
tematically and comprehensively identify, organise and
summarise the distribution of scientific evidence on any
topic. It can be the first step to conduct systematic reviews
or the framework to inform policy development [11–14].
The purpose of this evidence mapping project is to iden-
tify, describe and organise the current available evidence
about therapeutic interventions on sarcomas. This ap-
proach aims to determine the clinical questions assessed
in the scientific literature and the corresponding quality of
the supporting evidence, as well as to give general infor-
mation about their claimed effectiveness. This information
shall facilitate detecting research gaps and help stake-
holders in the decision-making process. For the sake of
clarification, this publication focuses exclusively on GIST
whereas the mapping of evidence on soft tissue sarcomas
will be addressed in future publications.
Methods
We conducted a mapping of evidence based on the meth-
odology proposed by GEM [12]. In consequence, we did a
comprehensive search strategy and assessed the quality of
the included SRs. We have only included systematic
reviews (with or without metanalysis) because they
provide the most reliable empirical evidence in order to
answer a specific research questions on therapeutic
effects. We divided the process in four stages (Fig. 1: Tasks
performed to map evidence in sarcomas).
Setting the boundaries and context of the evidence map
In order to framework our mapping project, we con-
sulted the 2013 World Health Organization (WHO)
classification [15], and the related clinical guidelines,
combined with the consultation to an oncologist with
expertise in sarcomas. With this information we
established the eligibility criteria for study inclusion.
We selected SRs assessing therapeutic interventions
in patients diagnosed with GIST, summarizing ran-
domized controlled trials (RCTs) as well as phase I
and II clinical trials, observational studies (including
cohorts studies, case control studies, cases series), or
case reports.
We used a broader definition of SR in order to obtain
the largest possible number of documents. The system-
atic reviews that conducted a search in at least two data-
bases were considered eligible. We included the most
updated review if more than one version was identified.
We excluded narrative reviews and systematic reviews
that were focused on prognosis or cost-effectiveness. We
also excluded studies on patients with Kaposi Sarcoma
and/or Ewing’s tumours because of their unique bio-
logical characteristics and management [16].
Fig. 1 Tasks performed to map evidence in sarcomas
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The selection was done independently by two
researchers.
Searching and selection of systematic reviews
We conducted searches in PubMed, EMBASE, The
Cochrane Library, and Epistemonikos from 1990 to
March 2016; the former was updated in November 2016.
The lower date boundary was chosen taking into account
that biological mechanisms were discovered in 1998 and
opened the use of biological agents as the key therapeutic
approach of GIST that completely changed the manage-
ment of the disease [17]. “However, we extended our
retrospective search until 1990 for establishing a reason-
able period of time to guarantee a higher sensitivity”.
We combined keywords and medical subject headings
(Mesh terms) for all types of sarcoma according to the
WHO 2013 classification [15]. We adapted the search
strategy in accordance with the specific characteristics of
each database. We did not limit searches by language. In
addition, a clinical expert (AL) was consulted to help in
identifying any other relevant reviews. Likewise, we
reviewed all references in the relevant articles to identify
potential additional reviews. Detailed search strategies
are reported in Additional file 1.
We managed the search results with the reference
manager software COVIDENCE [18]. After removing
duplicates, two reviewers (MB, NM) independently
screened all titles and abstracts to exclude irrelevant
reviews. Full texts of potentially relevant reviews were
obtained for a final decision. Disagreements were solved
through discussion and consensus; if necessary, an
additional reviewer (GU) was consulted. Reasons for
exclusion are clearly stated.
Data analysis
We built a data extraction form to register the main
characteristics and quality of included systematic reviews.
We tested a pre-defined data extraction form to ensure
consistency among reviewers in a pilot study with 20% of
eligible SRs. Two authors extracted data (MB, NM).
Disagreements were solved by discussion with a third
author (AL). We collected data at three levels:
a) General characteristics from systematic reviews:
authors, year of publication, type of systematic
review (with or without meta-analysis), objective,
search methods, design and number of included
studies, type and number of patients included,
and quality of the systematic review.
Two researchers (MB, NM) independently assessed
the methodological quality of the included reviews with
the AMSTAR tool. Disagreements were discussed until
consensus was reached. We calculated AMSTAR scores
by adding one point for each item rated as “yes” and no
point for items rated as “no”, “cannot answer”, or “not
applicable”, resulting in overall score ranging from 0 to
11. According to the total score, SRs were grouped in
three categories: low quality (0 to 3 points), 4 to 7 points
(moderate quality), and 8 to 11 points (high quality) [19].
b) Clinical questions assessed in the systematic reviews:
we converted the main aim reported in the included
systematic review and their eligibility criteria into
clinical questions framed in a PICO format
(specifying the four key components: population,
intervention, comparison and outcomes). The
obtained PICOs were classified in five therapeutic
scenarios with the help of a clinical expert (AL). We
then extracted details about the population
characteristics (e.g. adult population or children,
type of sarcoma, localisation of tumours), the
intervention and comparator (e.g. type of intervention
and comparison broadly categorised as chemotherapy,
surgery, radiotherapy and others, intention and
temporality of the intervention, and comparison,
drugs used in chemotherapy), and outcomes. For
descriptive purposes, we also categorised the
conclusions reported by the authors of the included
studies, into five categories: “inconclusive”, “no effect”,
“harmful”, “probably beneficial” and “beneficial” (see
Fig. 2 to see the criteria followed for this
categorization). Two authors completed this
assessment independently (MB, NM); disagreements
were solved by discussion until consensus was
reached. In any case, this judgement represents a
formal assessment about the evidence of interventions
benefits and harms.
c) Characteristics of other research questions addressed
in the systematic reviews, here named secondary
PICOs: we defined secondary research questions as
those for which all the elements of the PICO question
were provided but the conclusions about the direction
of the effect were described marginally in the article.
We extracted the same information described above
for the main research question.
Synthesising findings
We adapted every clinical question addressed in each in-
cluded review into a PICO format, which specifies the
types of population (participants), types of interventions
(and comparisons), and the types of outcomes of interest
[6]. We classified PICO questions according to the dis-
ease stage (localised or unresectable and/or metastatic
GIST) and summarised the findings for each included
review using: a) tables describing the characteristics of
the included systematic reviews, and another one with
the characteristics of all PICOs identified (main and
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secondary), and b) graphic display of the mapping based
on bubble plots. Each bubble in the chart represents one
included systematic review. This chart displays informa-
tion in three dimensions: (i) the rating of authors con-
clusions in the x-axis (“beneficial”, “probably beneficial”,
“harmful”, “no effect”, and “inconclusive”) (which are
further described in the data extraction section); (ii) the
AMSTAR assessment in the y-axis, and (iii) bubble size
according to the number of individual studies included
in the SR. Each bubble is also a pie chart that shows the
proportion of randomised controlled trials included in
the SR through a black bold line.
Results
We obtained 1791 records from the search after removal
of duplicates. Following screening of titles and abstracts,
143 articles were obtained in full text for a final decision.
A total of 41 reviews fulfilled the inclusion criteria for
the final analysis, of which 17 SRs are focused [17, 20–36]
on GIST, which developed search strategies until 2014. A
flow chart showing the selection of eligible reviews is
presented in Fig. 3: Flow chart outlining the study selec-
tion process. The list of the 102 reviews excluded on the
Evidence Mapping along with exclusion rationale is avail-
able in Additional file 2.
Characteristics and quality of systematic reviews
Among the 17 included SRs, 10 included a meta-
analysis. All SRs were published between 2005 and 2015
including studies conducted between 2001 and 2014.
Only two SRs reported a detailed search strategy that
allowed replication [23, 30]. A total of 66 individual
studies were included in the SR after considering over-
lapping or duplication of studies, of which 43 were ob-
servational studies, 15 were randomised controlled trials,
and 8 were phase II clinical trials.
Seven systematic reviews did not include any con-
trolled clinical trials [21, 23, 27, 30–32, 35], and among
them one did not include any study [23]. The 10
remaining systematic reviews included at least one clin-
ical trial. The number of patients included in the system-
atic reviews ranged from 233 to 2018 and all were
adults. Twelve SRs were conducted to assess chemother-
apy interventions [17, 20, 22–26, 28, 29, 32–34, 36] and
five evaluated surgical interventions [21, 27, 30, 31, 35].
Only 3 of 12 SRs assessed chemotherapy with a curative
intent [17, 24, 29], whereas in the remaining 9 SRs the
chemotherapy had a palliative intent [20, 22, 23, 25, 26,
28, 32–34, 36]. All SRs on surgery stated a curative
intent. All SRs assessed the clinical end-point and five
reported surgical intermediate outcomes, such as, blood
loss, earlier time to flatus, oral diet, etc. [21, 27, 30, 31, 35].
All SRs, except for two, reported overall survival [27, 35];
progression-free survival, response rate and local or distant
recurrence rate were reported in seven reviews [17, 22, 25,
26, 28, 33, 34, 36]; and quality of life was assessed only in
three SRs [22, 28, 32]. Two reviews reported data on
adverse events [23, 33]. Overall, quality of the included
SRs was moderate to high according to AMSTAR scores
(Fig. 4: Quality of the included SRs). The most frequent
drawbacks were: the failure to report the included and ex-
cluded studies [17, 20–22, 24, 27–31, 33–36], to declare
possible conflicts of interest [17, 23, 24, 30, 35], to evaluate
the likelihood of publication bias [17, 23, 30, 34, 36], and
to assess bias of individual studies for using it appropri-
ately in drawing conclusions [20, 22, 23, 34]. The charac-
teristics of the included SR are summarised in Table 1.
PICO questions included in systematic reviews
We extracted 14 PICO questions from related to GIST
SRs. The key characteristics of the PICOs are presented
in Table 2. Depending on the specific type of GIST, the
PICOs were grouped in the following five clinical
“Inconclusive”: direction of results differed across or within reviews due to conflicting 
results or limitations of individual studies. 
“No effect”: the conclusions provided evidence of no difference between intervention and 
comparator. 
“Harmful”: the conclusions were reported as clearly indicative of a harmful effect. 
“Probably beneficial”: the conclusions did not claim for firm benefits despite the reported 
positive treatment effect. . 
“Beneficial”: the conclusions reported a clear beneficial effect without major concerns 
regarding the supporting evidence.
Fig. 2 Classification of the conclusions according to results reported by authors
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scenarios, which include the entire clinical spectrum of
the disease (from non-metastatic to metastatic cancer):
(1)Patients with localised GIST: Five systematic reviews
[21, 27, 30, 31, 35] with a total of 28 observational
studies and no RCTs. All compared laparoscopic
resection versus open resection in GIST adult patients.
In general, the analysed outcomes were related to
surgery results (blood loss, time to flatus, operative
time, time to oral intake, length of hospital stay,
complication rate) and oncology outcomes (overall
survival, disease-specific survival). The overall
Fig. 3 Flow chart outlining the study selection process
Fig. 4 Quality of the included SRs
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conclusion from SRs was in favour of laparoscopic
resection and the effects were categorised as “beneficial”
[27, 30], and “probably beneficial” [21, 31, 35] due to
concerns about the lack of clinical trials.
(2)Patients with localised KIT (CD117)-positive GIST
after complete surgical resection: two SRs [24, 29]
which addressed the question of whether imatinib
should be given as adjuvant treatment versus surgery
alone without imatinib. In accordance with the risk
of recurrence, one SR assessed adjuvant imatinib for
overall population (all risk categories divided in
three subgroups: high, intermediate, and low) [24]
and the other focused on high-risk patients [29].
These two SRs based their conclusions on two
controlled trials, six uncontrolled trials and nine
observational studies. Overall, the results from the
included reviews favoured adjuvant imatinib for
patients at intermediate and high risk of recurrence,
and the conclusions could be categorised as “beneficial”
[24] and “probably beneficial” [29], respectively. For
patients at low risk of recurrence, the conclusion of
one systematic review [24] was rated as “no effect”
based on the subgroup analysis of one controlled trial.
One of these SR [29] also evaluated the duration of
adjuvant imatinib in this population, and qualified the
use of adjuvant imatinib for ≥3 years as “probably
beneficial” based on one controlled trial and one
observational study.
(3)Patients with unresectable and/or metastatic GIST: five
SRs evaluated different comparisons [17, 23, 32, 34, 36].
One SR assessed imatinib versus other standard
treatments (these included interventions for symptom
relief, best supportive care and placebo) and did not
find controlled trials that directly evaluated this
comparison [32]. Based on indirect comparison with
six uncontrolled trials and one observational study, the
use of imatinib in this population was classified as
“probably beneficial”. One SR assessed the use of
preoperative imatinib in the same population and
compared it with surgery alone, but no eligible
study addressing this issue was found [23]. Three
SR [17, 34, 36] with five RCTs in this category
assessed if high versus standard doses of imatinib
should be used. Overall, the high imatinib doses
were considered as “harmful” due to a misbalance
between benefits and harms.
(4)Patients with unresectable and/or metastatic GIST
after failure of imatinib due to resistance or
intolerance: four SRs addressing three different
comparisons [20, 25, 26, 28, 33]. Two SRs assessed
Sunitinib plus best supportive care versus imatinib at
escalated doses [20, 25, 26]. No studies directly
assessing this comparison were found. These two
SRs presented inconsistent conclusions based on
indirect comparisons from three trials and four
observational studies: “beneficial” in one SR [20] and
“no effect” in the other [25, 26]. One was Sunitinib
plus best supportive care (as defined by the
respective authors) versus best supportive care or
placebo. This comparison was assessed in three SRs
including one controlled trial and one observational
study [20, 28, 33]. Sunitinib plus best supportive
care was categorised as “beneficial” [28] and
“probably beneficial” [20, 33] for this population
due to limitations in the included studies. The third
comparison, masitinib versus sunitib was assessed
in one systematic review based on one controlled
trial, which concluded that masitinib is “probably
beneficial” [20].
(5)Patients with unresectable and/or metastatic GIST
after failure of imatinib and sunitinib due to
resistance or intolerance: three SRs comprising three
different comparisons [20, 22, 33]: a) Resumption of
imatinib versus placebo was rated as “probably
beneficial” in one systematic review including one
controlled trial [20]; b) regorafenib plus best
supportive care versus best supportive care or
placebo was rated as “probably beneficial” in three
SRs including one controlled trial and one uncontrolled
trial [20, 22, 33]; and c) nilotinib versus placebo was
rated as “no effect” and “inconclusive” by two SRs
including the same controlled trial [20, 33].
Discussion
Although no standard definition of evidence mapping
has emerged [11], these reviews share some common
characteristics: (a) they are appropriate for addressing
broad topics that are often too expansive for an individ-
ual systematic review; (b) they involve experts in the
area of study to set the inclusion and exclusion criteria;
(c) they are based on a systematic search; and (d) they
include user-friendly summaries of results.
Following these criteria, this evidence mapping has
identified, described and organised the current available
evidence for GIST, as part of a broader project aimed to
map the existing evidence for the treatment of soft-
tissue sarcomas. This mapping was based on 17 pub-
lished systematic reviews including 66 individual studies
conducted between 2001 and 2014. Regardless of the
type of evaluated intervention, three quarters of the in-
cluded studies in the SR were non-experimental (obser-
vational studies or uncontrolled clinical trials). This is a
phenomenon with important clinical and ethical impli-
cations since experimental studies are the best design to
evaluate the efficacy of new therapeutic options. For in-
stance, it is noteworthy that some clinical guidelines or
systematic reviews [3, 23, 32, 37–39] are already consid-
ering surgery resection as the current standard of care
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for localised GIST. However, according to the SR in-
cluded in this evidence mapping, none of the studies
used to support that recommendation about surgery
were randomised controlled trials; the total number of
included patients was less than 1000; and the results
consisted of intermediate surgery-related end-points ra-
ther than patient-centred outcomes. Another example is
the use of imatinib, a new biologic agent, in patients
with unresectable and/or metastatic GIST, evaluated in
one SR (37) that only included uncontrolled trials and
one observational study.
The majority of the interventions reported as “benefi-
cial” were palliative, probably due to a high proportion
of patients experiencing relapse or a metastatic process.
Another interesting finding was that only three studies
assessed the quality of life as an outcome and none of
them conducted an economic evaluation. Quality of life
measures are very important in cancer care because they
can provide information about the impact of diseases
and their treatment on the well-being of patients, and
complements efficacy and safety data [40]. Likewise, the
economic evaluation contributes to allocating resources
within society as efficiently as possible [41].
The majority of the interventions were reported by au-
thors as “beneficial” or “probably beneficial”. Only in
one comparison between biologic agents (sunitinib ver-
sus imatinib escalated doses in unresectable and/or
metastatic GIST after failure of imatinib) were the re-
sults controversial. As shown in the bubble plot, (Fig. 5)
one SR [20] concluded that sunitinib is “probably benefi-
cial” over imatinib at escalated doses, whereas another
one [25, 26] considered that sunitinib has no effect on
this type of patients. This discrepancy may be due to the
fact that Hislop SR [25, 26] was based on indirect com-
parisons from small phase II non-randomised studies,
whereas Abdel-Rahman SR [20] evaluated two retro-
spective observational comparative studies with direct
comparisons. Currently, sunitinib is usually recom-
mended after failure of escalated doses of imatinib for
these type of patients [5, 38, 42, 43].
Overall, the quality of the SRs according to AMSTAR
was moderate to high. However, the following domains
have yet to be improved: reporting the excluded studies
(only 4 studies out of 17 did it), the conflicts of interest,
and the assessment of the likelihood of publication bias
(only 12 did it). Similarly, 4 SRs did not report the qual-
ity of the included studies nor use it appropriately in for-
mulating conclusions, one of them being (31) the review
with more studies, the second one with more included
patients, and the most updated evidence about meta-
static GIST after failure of imatinib and sunitinib due to
resistance or intolerance. Although the evidence map-
ping does not usually include a quality assessment
process [9], we consider that any typology of review (e.g.
Fig. 5 Mapping of evidence of GIST
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rapid review, scoping review, umbrella review) should
evaluate this aspect in order to assess the reliability of
the conclusions; particularly in this case, where most
studies included in SRs on GIST sarcomas are non-
experimental and have small sample sizes.
Strengths
The Global Evidence Mapping Initiative (GEM) ap-
proach that we used is a rational, systematic and con-
stantly improved methodology. A recent systematic
review [11] showed that among the 16 documents that
met the common characteristics of evidence mapping,
seven referenced the GEM.
Some authors consider using highly specific search
strategies for evidence mapping [44, 45]. However, for
the purposes of our project, we preferred to make a sen-
sitive and adapted search strategy, taking into account
the fourth edition of the World Health Organization
Classification of Tumours of Soft Tissue and Bone [15]
and the clinical background and expertise of one of the
members of the research group, which revealed to be of
great value for clarifying content doubts. Likewise, we
used a broad definition of systematic review in order to
obtain the largest number of documents. Thus, we con-
sider that our search strategy is comprehensive as well
reproducible; hence, it is unlikely that any relevant sys-
tematic review on sarcomas has been missed. We used
the PICO format to organise and classify the information
obtained from SRs, which was very useful in establishing
thematic areas in this broad field. We also organised the
results in graphical formats and corroborated them with
other related clinical documents (e.g. clinical guidelines
and consensus). Following the recommendations of
GEM, we used two data extraction methods [12]: general
(for characteristics of included systematic reviews) and
specific (for main and secondary PICOs).
We added two uncommon components in evidence
mapping. Firstly, we rated the interventions included in
the systematic reviews as “beneficial”, “probably benefi-
cial”, “harmful”, “no effect” or “inconclusive” according to
the authors’ conclusions, irrespective of the reported out-
comes. It is important to highlight that we did not evalu-
ate the quality of the evidence of the studies included in
each SR, which makes this approach shorter than the one
required by a SR and appropriate for its descriptive pur-
poses although the provided information is less complete.
Secondly, we assessed the quality of included systematic
reviews with AMSTAR. This approach allows displaying
the results on a bubble plot for each SR with respect to
the other ones with the same comparison, providing a
quick view of the existing evidence and their quality.
According to this experience, the most time-consuming
phases were classifying the interventions and extracting
the secondary PICOs. Although the time spent in an
evidence mapping can vary depending on the topic, we
recommend elaborating a protocol before starting the pro-
ject and performing a pilot study as we did.
Limitations
Some limitations were faced in this study. Firstly, our
search for SRs was conducted in 2016 but their respect-
ive searches were done much earlier, being the most up-
dated search until 2014. Therefore, we cannot guarantee
a comprehensive identification of all primary studies
about sarcomas that may have been published beyond
this date. However, we believe that these limitations
would not substantially change the main results of this
evidence mapping. Secondly, as it is a characteristic of
all evidence mapping methodologies, we did not assess
the quality of the evidence supporting the conclusions,
which would have required the use of some complemen-
tary criteria such as GRADE [46]. In order to provide
some qualitative information about the validity of SR,
we assessed them through AMSTAR, which is a vali-
dated tool [19]. However, a noteworthy drawback of our
evidence mapping is that it merely organises and de-
scribes the available evidence as is reported by respective
authors. This explains why many treatments are pre-
sented as beneficial even they are based on non-
experimental studies.
Therefore, the main practical applications of evidence
mapping are: to orientate further research projects; to
stimulate the design of more focused RCT and other
rigorous evaluative studies to fill the detected gaps in
knowledge; to provide useful comprehensive information
for establishing priorities when funding research in this
field; to compare the obtained results with the recom-
mendations from clinical guideline in order to identify
and solve potential contradictions between them; to help
future authors of SRs, rapid reviews and scoping reviews
avoiding redundant efforts and improve efficiency; and,
to explore innovative tools and friendly formats to dis-
seminate the results to interested stakeholders.
Conclusions
From a practical point of view, this evidence mapping
shows a relatively high consistency of effects reported by
the different SRs, except for two SRs (comparing suniti-
nib versus escalated imatinib in GIST metastatic patients
after failure of imatinib) (Fig. 5). The quality of the in-
cluded SRs based on the AMSTAR criteria is moderate to
high, which gives some confidence about the validity of
their results. The scarce number of clinical trials in this
field is remarkable, and we consider that the most
important clinical questions have been covered.
In conclusion, the most common type of study to
evaluate therapeutic interventions in GIST sarcomas has
been non-experimental studies (observational studies or
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uncontrolled clinical trials), frequently based on small
samples sizes. The quality of the included SR was moder-
ate to high. The evidence mapping is a useful and reliable
methodology to identify and present the current available
evidence about therapeutic interventions. Therefore, these
results can be helpful to facilitate any review process that
may be conducted and orientate research priorities.
Additional files
Additional file 1: Search strategies. (DOCX 44 kb)
Additional file 2: SRs excluded. (DOCX 18 kb)
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